Wanli Tang represents pharmaceutical and biotechnology companies of all sizes on the procurement and protection of intellectual property. She develops and manages global patent portfolios for clients and coordinates strategies to meet clients' IP needs and business goals. Wanli counsels on issues including patentability, validity, enforceability, infringement, and freedom-to-operate. She also assists client with investment- and public offering-related diligence investigations.
Wanli conducts prelitigation analyses and represents clients in offensive and defensive post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), including inter partes reviews (IPRs). She works closely with expert witnesses in preparation for depositions or declarations, coordinates document discovery, and drafts petitions and briefings.
Wanli prepares and prosecutes patent applications throughout the world and has been involved in opposition and appeal proceedings in jurisdictions such as Europe, China, and Japan. She helps clients obtain patent protection in areas including green technology, drug discovery, and diagnostics. She works daily with companies actively developing or implementing technologies involving small molecules, vaccines, antibodies, peptides, and stem cells in areas such as oncology, autoimmune diseases, and metabolic disorders. Wanli keeps abreast of biotechnology breakthroughs and has in-depth understanding of discoveries in fields including cancer immunology, gene editing, precision medicine, and microbiome.
Prior to practicing law, Wanli obtained her Ph.D. in Molecular Cancer Biology from Duke University within four years, coauthored more than 10 peer-reviewed scientific publications, and was named Robert Fitzgerald Scholar for her distinguished research.
Pharmaceutical Compound Nonobvious Absent Evidence Suggesting Specific Modification to Prior Art Compound, PTAB Litigation Blog
- September 17, 2015Means-Plus-Function Patent Claims After Williamson: Navigating the New Standard. Strafford Webinar
- May 7, 2015IP Roundtable - Emerging Trends in IP Valuation and Risk Analysis
- Duke University (J.D. magna cum laude 2013; Duke Law Journal; Ph.D. in Molecular Cancer Biology 2010); Tsinghua University, China (B.S. in Biological Sciences and Biotechnology 2005)
- California and registered to practice before the U.S. Patent and Trademark Office